Search company, investor...

Founded Year

2008

Stage

Series B | Alive

Total Raised

$561.5M

Last Raised

$120M | 3 yrs ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+20 points in the past 30 days

About Biosplice Therapeutics

Biosplice Therapeutics is a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases. Its scientific platform is based on biological discoveries that govern tissue specialization and enable it to selectively eliminate harmful proteins using small molecules. It was formerly known as Wintherix & Epitherix. It was founded in 2008 and is based in San Diego, California.

Headquarters Location

9360 Towne Centre Drive Suite 160

San Diego, California, 92121,

United States

858-926-2900

Loading...

Loading...

Biosplice Therapeutics Patents

Biosplice Therapeutics has filed 131 patents.

The 3 most popular patent topics include:

  • transcription factors
  • g protein coupled receptors
  • clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/26/2022

11/21/2023

Benzamides, Proteinogenic amino acids, Orthorhombic minerals, Glucogenic amino acids, Iron minerals

Grant

Application Date

7/26/2022

Grant Date

11/21/2023

Title

Related Topics

Benzamides, Proteinogenic amino acids, Orthorhombic minerals, Glucogenic amino acids, Iron minerals

Status

Grant

Latest Biosplice Therapeutics News

Samil's partner Biosplice Therapeutics proves efficacy of osteoarthritis drug in phase 3 trial

Dec 4, 2023

닫기 Samil Pharmaceutical said Monday that its U.S. partner firm Biosplice Therapeutics  confirmed the efficacy of Lorecivivint, a drug candidate for knee osteoarthritis, in a phase 3 study called OA-07. These results were recently revealed during the American College of Rheumatology (ACR) meeting held in San Diego, California, on Nov. 13. (Credit: Getty Images) Biosplice Therapeutics developed Lorecivivint, and in March 2021, Samil Pharmaceutical obtained exclusive rights to license and market the drug in Korea. Lorecivivint is a Cdc-Like Kinase (CLK)/Dual specificity tyrosine-phosphorylation-regulated kinase (DYRK) inhibitor. It has a mechanism of action that modulates Wingless and int (Wnt) signaling and is being developed as a disease-modifying osteoarthritis drug (DMOAD). OA-07 is an extension study in 276 patients who completed the phase 3 OA-11 study in the U.S. The study aimed to assess Lorecivivint when administered annually over a three-year period. In Year 1 of OA-07, the study arm received 0.07 mg of Lorecivivint, while the control arm received a placebo. In Year 2 of the OA-07 trial, the treatment and control groups received 0.07 mg of Lorecivivint. While the OA-07 trial was ongoing, the results of the previous trial, OA-11, remained double-blind. Clinical results showed a minimum joint space width (mJSW) of -0.06 mm in the treatment group received Lorecivivint 0.07 mg once a year for three years and a mJSW of -0.21 mm in the placebo control group. OA-07 phase 3 clinical results of treatment with Lorecivivint in all subjects (Credit: Samil Pharmaceutical) Assuming the control group received a placebo for 36 months, Samil said the difference in mJSW between the trial and placebo groups was 0.26 mm, which was clinically and statistically significant. The mJSW is measured by x-ray, showing knee osteoarthritis progression based on its width. A smaller mJSW indicates more severe osteoarthritis progression, while an increased mJSW indicates improved osteoarthritis. "These results indicate that repeated injections of Lorecivivint may provide both structural changes and symptomatic benefits," said Yusuf Yazici, a researcher of Biosplice Therapeutics, who presented the phase 3 results. "We are excited to continue to study Lorecivivint as a treatment option for knee osteoarthritis." "The clinical results are significant as they confirm long-term safety and efficacy. It is expected to become a meaningful new drug portfolio for Samil Pharmaceutical, which has exclusive domestic rights," a Samil official said.

Biosplice Therapeutics Frequently Asked Questions (FAQ)

  • When was Biosplice Therapeutics founded?

    Biosplice Therapeutics was founded in 2008.

  • Where is Biosplice Therapeutics's headquarters?

    Biosplice Therapeutics's headquarters is located at 9360 Towne Centre Drive, San Diego.

  • What is Biosplice Therapeutics's latest funding round?

    Biosplice Therapeutics's latest funding round is Series B.

  • How much did Biosplice Therapeutics raise?

    Biosplice Therapeutics raised a total of $561.5M.

  • Who are the investors of Biosplice Therapeutics?

    Investors of Biosplice Therapeutics include Sands Capital, Eventide Asset Management, aMoon Fund, SymBiosis, Verition Fund Management and 7 more.

  • Who are Biosplice Therapeutics's competitors?

    Competitors of Biosplice Therapeutics include Chordia Therapeutics and 1 more.

Loading...

Compare Biosplice Therapeutics to Competitors

L
Lubris BioPharma

Lubris BioPharma operates as a biopharmaceutical company. It develops recombinant human lubricin for the treatment of dry eye, osteoarthritis, surgical adhesions, xerostomia, and pericarditis. It was founded in 2011 and is based in Weston, Massachusetts.

C
Chordia Therapeutics

Chordia Therapeutics is a bio-venture company specializing in cancer research and development. Chordia's programs include preclinical CDC-like kinase (CLK) inhibitors with applications in cancer and an adult T-cell leukemia-lymphoma drug. The company serves customers in the healthcare sector. It was founded in 2017 and is based in Fujisawa, Japan.

Oyster Point Pharma Logo
Oyster Point Pharma

Oyster Point Pharma (NASDAQ: OYST) is a clinical-stage pharmaceutical company. It focuses on the discovery, development, and commercialization of therapies to treat diseases with high unmet needs. The company's initial focus is to develop therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. The company was founded in 2015 and is based in Princeton, New Jersey. In January 2023, Oyster Point Pharma was acquired by Viatris.

Aldeyra Therapeutics Logo
Aldeyra Therapeutics

Aldeyra Therapeutics is a company focused on the discovery and development of innovative therapies for immune-mediated diseases in the healthcare sector. The company's main offerings include the development of medicines that modulate immunological systems to treat ocular and systemic conditions such as dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy. Aldeyra primarily serves the healthcare industry, particularly in the area of immune-mediated diseases. It is based in Lexington, Massachusetts.

Bioventus Logo
Bioventus

Bioventus (NASDAQ: BVS) is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. The company has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.